NCT06701890

Observational Study of Travellers Pathologies

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 11,000 (estimated)
• Sponsor: Institut Pasteur · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues. The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.

Detailed description

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues. The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory. Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern. To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR. * EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected. * EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.

Conditions

• Travel-Related Illness

Interventions

Type	Name	Description
OTHER	Blood sample collection	16 mL at inclusion 16 mL at 1 month after return from travel
OTHER	Fecal sample collection	1 sample at inclusion 1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel

Timeline

• Start date: 2024-12-09
• Primary completion: 2034-12-01
• Completion: 2036-12-01
• First posted: 2024-11-22
• Last updated: 2025-05-01

Locations

1 site across 1 country: France